Organon & Co.

34.57-0.2200-0.63%Vol 798.00K1Y Perf 13.88%
Jun 29th, 2022 16:03 DELAYED
BID34.00 ASK35.95
Open35.05 Previous Close34.57
Pre-Market- After-Market-
 - -%  - -
Target Price
39.14 
Analyst Rating
Moderate Buy 1.86
Potential %
13.22 
Finscreener Ranking
★★★★     53.39
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     62.38
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     54.99
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
★★★+     48.04
Price Range Ratio 52W %
55.63 
Earnings Rating
Market Cap8.77B 
Earnings Date
11th Aug 2022
Alpha0.03 Standard Deviation0.13
Beta0.63 

Today's Price Range

34.4335.05

52W Range

28.4239.48

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-1.00%
1 Month
-11.13%
3 Months
-3.46%
6 Months
12.50%
1 Year
13.88%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
OGN34.57-0.2200-0.63
AAPL139.231.79001.30
GOOG2 245.13-6.3000-0.28
MSFT260.263.78001.47
XOM88.12-3.3800-3.69
WFC39.71-0.4700-1.17
JNJ176.990.05000.03
FB196.640.99000.51
GE63.69-2.1900-3.32
JPM115.30-0.5200-0.45
Earnings HistoryEstimateReportedSurprise %
Q01 20221.311.6525.95
Q04 20211.251.379.60
Q03 20211.441.6715.97
Q02 20211.491.7215.44
Q01 20211.571.56-0.64
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Aug 2022
Estimated EPS Next Report1.27
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume798.00K
Shares Outstanding253.64K
Shares Float224.79M
Trades Count13.01K
Dollar Volume27.60M
Avg. Volume1.36M
Avg. Weekly Volume1.23M
Avg. Monthly Volume1.34M
Avg. Quarterly Volume1.51M

Organon & Co. (NYSE: OGN) stock closed at 34.57 per share at the end of the most recent trading day (a -0.63% change compared to the prior day closing price) with a volume of 798.00K shares and market capitalization of 8.77B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 9950 people. Organon & Co. CEO is Kevin Ali.

The one-year performance of Organon & Co. stock is 13.88%, while year-to-date (YTD) performance is 13.53%. OGN stock has a five-year performance of %. Its 52-week range is between 28.42 and 39.475, which gives OGN stock a 52-week price range ratio of 55.63%

Organon & Co. currently has a PE ratio of 7.00, a price-to-book (PB) ratio of 1.84, a price-to-sale (PS) ratio of 1.41, a price to cashflow ratio of 8.40, a PEG ratio of 2.32, a ROA of 13.20%, a ROC of 13.88% and a ROE of 81.02%. The company’s profit margin is 20.42%, its EBITDA margin is 32.50%, and its revenue ttm is $6.37 Billion , which makes it $25.09 revenue per share.

Of the last four earnings reports from Organon & Co., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.27 for the next earnings report. Organon & Co.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Organon & Co. is Moderate Buy (1.86), with a target price of $39.14, which is +13.22% compared to the current price. The earnings rating for Organon & Co. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Organon & Co. has a dividend yield of 3.16% with a dividend per share of $1.12 and a payout ratio of -%.

Organon & Co. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.79, ATR14 : 1.06, CCI20 : -26.95, Chaikin Money Flow : -0.01, MACD : -0.36, Money Flow Index : 50.82, ROC : -2.51, RSI : 46.43, STOCH (14,3) : 41.43, STOCH RSI : 0.62, UO : 49.58, Williams %R : -58.57), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Organon & Co. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (57.14 %)
5 (62.50 %)
4 (57.14 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (42.86 %)
3 (37.50 %)
3 (42.86 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.86
Moderate Buy
1.75
Moderate Buy
1.86

Organon & Co.

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.

CEO: Kevin Ali

Telephone: +1 551 430-6900

Address: 30 Hudson Street, Jersey City 07302, NJ, US

Number of employees: 9 950

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

58%42%

Bearish Bullish

58%42%

News

Stocktwits